In last trading session, Esperion Therapeutics Inc (NASDAQ:ESPR) saw 2.03 million shares changing hands with its beta currently measuring 1.04. Company’s recent per share price level of $1.90 trading at $0.03 or 1.60% at ring of the bell on the day assigns it a market valuation of $374.37M. That closing price of ESPR’s stock is at a discount of -107.37% from its 52-week high price of $3.94 and is indicating a premium of 16.84% from its 52-week low price of $1.58.

For Esperion Therapeutics Inc (ESPR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.78. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.16 in the current quarter.

Esperion Therapeutics Inc (NASDAQ:ESPR) trade information

Upright in the green during last session for gaining 1.60%, in the last five days ESPR remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $1.90 price level, adding 1.55% to its value on the day. Esperion Therapeutics Inc’s shares saw a change of -13.64% in year-to-date performance and have moved 6.15% in past 5-day. Esperion Therapeutics Inc (NASDAQ:ESPR) showed a performance of -14.03% in past 30-days.

Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 76.25% to its current value. Analysts have been projecting 8 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -321.05% in reaching the projected high whereas dropping to the targeted low would mean a loss of -321.05% for stock’s current value.

Esperion Therapeutics Inc (ESPR) estimates and forecasts

This year revenue growth is estimated to rise 179.14% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 61.58M for the same. And 5 analysts are in estimates of company making revenue of 50.64M in the next quarter. Company posted 32.25M and 137.74M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 23.09% during past 5 years.

Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders

WASATCH ADVISORS LP is the top institutional holder at ESPR for having 16.86 million shares of worth $37.44 million. And as of 2024-06-30, it was holding 8.9319 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 13.98 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.2617 of outstanding shares, having a total worth of $31.04 million.

On the other hand, Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 6.68 shares of worth $12.68 million or 3.39% of the total outstanding shares. The later fund manager was in possession of 6.18 shares on Sep 30, 2024 , making its stake of worth around $11.74 million in the company or a holder of 3.14% of company’s stock.